A citation-based method for searching scientific literature

Jacek Gronwald, Nadine Tung, William D Foulkes, Kenneth Offit, Ruth Gershoni, Mary Daly, Charmaine Kim-Sing, Hakan Olsson, Peter Ainsworth, Andrea Eisen, Howard Saal, Eitan Friedman, Olufunmilayo Olopade, Michael Osborne, Jeffrey Weitzel, Henry Lynch, Parviz Ghadirian, Jan Lubinski, Ping Sun, Steven A Narod. Int J Cancer 2006
Times Cited: 177







List of co-cited articles
1026 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
882
44

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
41

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
S A Narod, J S Brunet, P Ghadirian, M Robson, K Heimdal, S L Neuhausen, D Stoppa-Lyonnet, C Lerman, B Pasini, P de los Rios,[...]. Lancet 2000
388
39

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Kelly Metcalfe, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Ivo Olivotto, Ellen Warner, Olufunmilayo I Olopade, Andrea Eisen, Barbara Weber, Jane McLennan,[...]. J Clin Oncol 2004
424
36


Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
722
33

Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Lori J Pierce, Albert M Levin, Timothy R Rebbeck, Merav A Ben-David, Eitan Friedman, Lawrence J Solin, Eleanor E Harris, David K Gaffney, Bruce G Haffty, Laura A Dawson,[...]. J Clin Oncol 2006
211
28

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
28

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
27

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Andrea Eisen, Jan Lubinski, Jan Klijn, Pal Moller, Henry T Lynch, Kenneth Offit, Barbara Weber, Tim Rebbeck, Susan L Neuhausen, Parviz Ghadirian,[...]. J Clin Oncol 2005
309
26

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Timothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, Steven A Narod, Laura Van't Veer, Judy E Garber, Gareth Evans, Claudine Isaacs, Mary B Daly, Ellen Matloff,[...]. N Engl J Med 2002
26

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Monika K Graeser, Christoph Engel, Kerstin Rhiem, Dorothea Gadzicki, Ulrich Bick, Karin Kast, Ursula G Froster, Bettina Schlehe, Astrid Bechtold, Norbert Arnold,[...]. J Clin Oncol 2009
194
26

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander,[...]. J Clin Oncol 2013
113
26

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
L C Hartmann, T A Sellers, D J Schaid, T S Frank, C L Soderberg, D L Sitta, M H Frost, C S Grant, J H Donohue, J E Woods,[...]. J Natl Cancer Inst 2001
485
25

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Amy Finch, Mario Beiner, Jan Lubinski, Henry T Lynch, Pal Moller, Barry Rosen, Joan Murphy, Parviz Ghadirian, Eitan Friedman, William D Foulkes,[...]. JAMA 2006
405
24


Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
366
22

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
H Meijers-Heijboer, B van Geel, W L van Putten, S C Henzen-Logmans, C Seynaeve, M B Menke-Pluymers, C C Bartels, L C Verhoog, A M van den Ouweland, M F Niermeijer,[...]. N Engl J Med 2001
639
22

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
22

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
Mieke Kriege, Cecile T M Brekelmans, Carla Boetes, Peter E Besnard, Harmine M Zonderland, Inge Marie Obdeijn, Radu A Manoliu, Theo Kok, Hans Peterse, Madeleine M A Tilanus-Linthorst,[...]. N Engl J Med 2004
21

Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Kathleen E Malone, Colin B Begg, Robert W Haile, Ake Borg, Patrick Concannon, Lina Tellhed, Shanyan Xue, Sharon Teraoka, Leslie Bernstein, Marinela Capanu,[...]. J Clin Oncol 2010
111
21

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Steven A Narod, Marie-Pierre Dubé, Jan Klijn, Jan Lubinski, Henry T Lynch, Parviz Ghadirian, Diane Provencher, Ketil Heimdal, Pal Moller, Mark Robson,[...]. J Natl Cancer Inst 2002
226
19

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
19

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
C T M Brekelmans, M M A Tilanus-Linthorst, C Seynaeve, A vd Ouweland, M B E Menke-Pluymers, C C M Bartels, M Kriege, A N van Geel, C W Burger, A M M Eggermont,[...]. Eur J Cancer 2007
148
19

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Lori J Pierce, Kelly-Anne Phillips, Kent A Griffith, Saundra Buys, David K Gaffney, Meena S Moran, Bruce G Haffty, Merav Ben-David, Bella Kaufman, Judy E Garber,[...]. Breast Cancer Res Treat 2010
106
19

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005
271
18

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski, Ewa Grzybowska, Magdalena Budryk, Malgorzata Stawicka, Tomasz Mierzwa, Marek Szwiec, Rafal Wisniowski, Monika Siolek,[...]. J Clin Oncol 2010
378
18

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
18

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
880
18

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
Andrea Eisen, Jan Lubinski, Jacek Gronwald, Pal Moller, Henry T Lynch, Jan Klijn, Charmaine Kim-Sing, Susan L Neuhausen, Lucy Gilbert, Parviz Ghadirian,[...]. J Natl Cancer Inst 2008
130
18

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Kerryn W Reding, Jonine L Bernstein, Bryan M Langholz, Leslie Bernstein, Robert W Haile, Colin B Begg, Charles F Lynch, Patrick Concannon, Ake Borg, Sharon N Teraoka,[...]. Breast Cancer Res Treat 2010
40
45

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Ellen Warner, Donald B Plewes, Kimberley A Hill, Petrina A Causer, Judit T Zubovits, Roberta A Jong, Margaret R Cutrara, Gerrit DeBoer, Martin J Yaffe, Sandra J Messner,[...]. JAMA 2004
773
17

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
T C van Sprundel, M K Schmidt, M A Rookus, R Brohet, C J van Asperen, E J Th Rutgers, L J Van't Veer, R A E M Tollenaar. Br J Cancer 2005
183
17

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Kelly A Metcalfe, Daphna Birenbaum-Carmeli, Jan Lubinski, Jacek Gronwald, Henry Lynch, Pal Moller, Parviz Ghadirian, William D Foulkes, Jan Klijn, Eitan Friedman,[...]. Int J Cancer 2008
250
17

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
16

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
K Metcalfe, S Gershman, H T Lynch, P Ghadirian, N Tung, C Kim-Sing, O I Olopade, S Domchek, J McLennan, A Eisen,[...]. Br J Cancer 2011
126
16

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Mark E Robson, Pierre O Chappuis, Jaya Satagopan, Nora Wong, Jeff Boyd, John R Goffin, Clifford Hudis, David Roberge, Larry Norton, Louis R Bégin,[...]. Breast Cancer Res 2004
212
15

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
15

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
528
15

Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
L C Hartmann, D J Schaid, J E Woods, T P Crotty, J L Myers, P G Arnold, P M Petty, T A Sellers, J L Johnson, S K McDonnell,[...]. N Engl J Med 1999
928
14

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
14

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
13

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
M O Leach, C R M Boggis, A K Dixon, D F Easton, R A Eeles, D G R Evans, F J Gilbert, I Griebsch, R J C Hoff, P Kessar,[...]. Lancet 2005
706
13

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Bruce G Haffty, Elizabeth Harrold, Atif J Khan, Pradip Pathare, Tanya E Smith, Bruce C Turner, Peter M Glazer, Barbara Ward, Daryl Carter, Ellen Matloff,[...]. Lancet 2002
198
13

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, Laura Fulford, Frederique Penault-Llorca, Marc van der Vijver, Suzanne Parry, Timothy Bishop, Javier Benitez, Carmen Rivas, Yves-Jean Bignon,[...]. Clin Cancer Res 2005
446
12

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
12


Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
574
12

Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.
Ellen Warner, Kimberley Hill, Petrina Causer, Donald Plewes, Roberta Jong, Martin Yaffe, William D Foulkes, Parviz Ghadirian, Henry Lynch, Fergus Couch,[...]. J Clin Oncol 2011
165
12

Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
John R McLaughlin, Harvey A Risch, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry Lynch, Beth Karlan, David Fishman, Barry Rosen, Susan L Neuhausen,[...]. Lancet Oncol 2007
143
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.